Blog
RSS FeedPosted by Michael Wonder on 23 Dec 2017
Institute for Clinical and Economic Review's final report on VMAT2 inhibitors for tardive dyskinesia calls for manufacturer and payer action to lower prices and assure adequate access
22 December 2017 - Evidence suggests drugs offer short-term benefits but are vastly overpriced, leading to “low value” designation and triggering ...
Posted by Michael Wonder on 15 Dec 2017
Institute for Clinical and Economic Review to assess elagolix for management of endometriosis
14 December 2017 - Open input now being accepted until 8 January 2018. ...
Posted by Michael Wonder on 05 Dec 2017
Institute for Clinical and Economic Review posts draft scoping documents for two reviews: CGRP inhibitors for migraine and update to prior review of plaque psoriasis treatments
4 December 2017 - Documents open to public comment until 22 December 2017. ...
Posted by Michael Wonder on 22 Nov 2017
Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patient
21 November 2017 - Report will be subject to public deliberation during New England CEPAC meeting on 5 December 2017. ...
Posted by Michael Wonder on 10 Nov 2017
Institute for Clinical and Economic Review to assess erenumab for migraine prevention; guselkumab and tildrakizumab for plaque psoriasis
9 November 2017 - Open Input now being accepted on both topics; both reviews to be subject to public deliberation at ...
Posted by Michael Wonder on 06 Nov 2017
Institute for Clinical and Economic Review final report recommends enhanced coverage of certain non-drug management options for chronic low back pain
6 November 2017 - Evidence suggests safe and effective treatments include acupuncture, cognitive behavioral therapy, mindfulness-based stress reduction, and yoga. ...
Posted by Michael Wonder on 01 Nov 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of tezacaftor and lumacaftor for cystic fibrosis
31 October 2017 - Document open to public comment until 20 November 2017. ...
Posted by Michael Wonder on 31 Oct 2017
Institute for Clinical and Economic Review announces new 13.9 million dollar grant from the Laura and John Arnold Foundation
31 October 2017 - Expanded funding enables ICER value assessments for all newly approved medicines in the US. ...
Posted by Michael Wonder on 12 Oct 2017
Institute for Clinical and Economic Review to evaluate cystic fibrosis treatments in upcoming report
12 October 2017 - Report expected to review tezacaftor, lumacaftor, and ivacaftor (Vertex Pharmaceuticals); Open Input accepted until 27 October. ...
Posted by Michael Wonder on 03 Oct 2017
Institute for Clinical and Economic Review releases draft evidence report on treatments for tardive dyskinesia
2 October 2017 - Public comment period now open until 30 October; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 30 Sep 2017
Institute for Clinical and Economic Review's final report confirms inadequate evidence to compare outcomes of PARP inhibitors for ovarian cancer, highlights poor cost-effectiveness, particularly for maintenance therapy
29 September 2017 - The ICER has issued a final evidence report assessing the comparative clinical effectiveness and value of ...
Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts updated economic analyses for PCSK9 inhibitor evolocumab, finds less favourable cost-effectiveness
11 September 2017 - To reflect new clinical trial evidence, updated ICER value-based price benchmark for a year of treatment ...
Posted by Michael Wonder on 09 Sep 2017
Should value frameworks take a ‘societal perspective’?
6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...
Posted by Michael Wonder on 31 Aug 2017
Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications
30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three ...
Posted by Michael Wonder on 12 Aug 2017
Institute for Clinical and Economic Review to evaluate comparative clinical effectiveness and value of emicizumab for haemophilia A
11 August 2017 - Open input period now open until 6 September 2017. ...